Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck earnings and sales Q2 views, with the Dow Jones drug giant raising full-year guidance. MRK stock rose early Friday.

Merck Earnings Top; Dow Drug Giant Raises Guidance

Pharmaceutical giant Merck beat Wall Street expectations in the second quarter and raised its overall earnings guidance for the year, saying Friday that the worst of the coronavirus pandemic is behind it.

Pharma giant Merck raises 2020 outlook, saying the worst of the coronavirus impact is behind it

Shares of Merck & Co. Inc. MRK, -0.45% rallied 3.4% in premarket trading Friday, after the drug giant reported second-quarter profit and sales that beat expectations, while pharmaceutical sales fell from the effects of the COVID-19 pandemic, and raised its full-year outlook.

Merck's stock rallies after

Merck's stock rallies after profit and sales beats, raised outlook

Merck & Co Inc reported a 7.6% fall in second-quarter sales on Friday as a drop in visits to doctors' offices because of the COVID-19 pandemic hurt sales of several important drugs.

Merck quarterly sales fall 7.6% as pandemic cuts doctor visits

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2020 Financial Results

 Merck Announces Second-Quarter 2020 Financial Results

On Friday, July 31, Merck & Co (NYSE: MRK) will release its latest earnings report.

Merck & Co's Earnings Outlook

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)

Merck Announces Two US Regulatory Milestones for KEYTRUDA® (pembrolizumab) in Triple-Negative Breast Cancer (TNBC)

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Breakthrough Therapy Designation to Merck’s MK-6482 for Certain Patients With Von Hippel-Lindau Disease-Associated RCC

FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma

The new payout will be dispensed in October.

Merck Declares Fresh Dividend; Yield Is 3.1%

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Fourth-Quarter 2020 Dividend

Merck Announces Fourth-Quarter 2020 Dividend

Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.

How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?

AstraZeneca

Gilead Sciences

GlaxoSmithKline

Eli Lilly

Pfizer

Sanofi

Several major U.S. drugmakers will report second-quarter results this week, with investors eager for fresh details from Pfizer Inc , Merck & Co and others on their efforts to develop vaccines and therapies against the novel coronavirus.

U.S. drugmaker earnings heat up this week with spotlight on vaccine news

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Merck (MRK) Q2 Earnings Expected to Decline

Johnson & Johnson

Moderna

Drug company executives insisted Tuesday they aren’t cutting corners in fast-tracking development of potential vaccines to prevent infection of the coronavirus.

Pharma executives promise Congress they aren't cutting corners in fast tracking coronavirus vaccine

FDA decision on Merck (MRK) and its Germany-based partner Bayer's vericiguat as a treatment to reduce heart failure is expected in January 2021.

Merck's NDA for Heart Failure Candidate Gets Priority Review

Bristol-Myers

In a previous article published in GuruFocus, I looked at the top five pharma companies on EvaluatePharma’s list ranked by sales the firms are expected to achieve in 2026.

Pharma Companies Look to Blockbusters to Drive Sales

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat

FDA Grants Priority Review to Merck’s New Drug Application for Vericiguat

Novocure and Dow Jones pharmaceutical giant Merck announced a collaboration in non-small cell lung cancer treatment Wednesday — prodding shares of Novocure and Merck stock to pop.
The post Dow Jones Giant Merck Inks A New Deal In Lung Cancer — And Shares Pop appeared first on Investor's Business Daily.

Dow Jones Giant Merck Inks A New Deal In Lung Cancer — And Shares Pop

Abbott Labs

Large drugmakers are hoping to stop a looming global crisis that could be much worse than COVID-19.

Why Big Pharma's $1 Billion Bet to Prevent a Bacterial Pandemic Matters for You

FDA grants priority review to Merck's (MRK) regulatory application seeking label expansion of Keytruda as second-line treatment for relapsed or refractory classical Hodgkin lymphoma.

Merck's Keytruda Gets Priority Review for Lymphoma Indication

Merck: Amazing Oncology Division, Underwhelming Dividend Opportunity

A new $1 billion fund backed by 20 drugmakers including Eli Lilly, Merck and Pfizer is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday.

New $1 billion fund aims to steer antibiotic companies in a tough market

A new $1 billion fund backed by 20 drugmakers including Merck & Co Inc and Pfizer Inc is aiming to bolster struggling antibiotic companies and sustain a pipeline for new treatments, an industry group said on Thursday.

News for Merck Stock (MRK)